代谢干扰,体重指数和炎症对COVID-19后的认知功能的影响:一项随机对照试验对沃尔提奥谢进行了随机对照
Angela T H Kwan1,2, Gia Han Le1,3, Ziji Guo1,4
1Brain and Cognition Discovery Foundation, 77 Bloor Street West, Suite 617, Toronto, ON, M5S 1M2, Canada.
Annals of general psychiatry
|February 29, 2024
概括
在COVID-19后病情 (PCC) 患者中,西改善了代谢功能障碍和炎症的认知缺陷. 这一发现为管理持续的PCC症状和认知障碍提供了希望.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 公共卫生 公共卫生
背景情况:
- 后COVID-19条件 (PCC) 提出了重要的认知和情绪挑战,与相关的代谢功能障碍和炎症.
- 目前针对PCC的治疗方法缺乏监管部门的批准,这凸显了医疗需求尚未得到满足.
- 在PCC患者中经常观察到体质指数 (BMI) 升高.
研究的目的:
- 调查西在改善PCC患者认知缺陷方面的疗效.
- 在PCC患者中探索沃尔提奥塞丁的作用与代谢功能障碍,炎症和BMI之间的相互作用.
主要方法:
- 一项为期8周的随机,双盲,安慰剂对照试验的后期分析,涉及147名加拿大成年人,患有世卫组织定义的PCC症状.
- 参与者每天接受西 (5-20毫克) 或安慰剂.
- 主要结局是通过从基线到终点的数字符号替代测试 (DSST) 得分的变化来衡量.
主要成果:
- 观察到时间,治疗和治疗x时间xCRP xTG-HDL xBMI相互作用对认知功能的显著影响.
- 与安慰剂相比,西治疗在研究终点上导致认知功能显著改善.
- 该疗法在DSST得分中显示出0.621 (p=0.047) 的平均差异.
结论:
- 西显著改善了PCC患者的认知缺陷,特别是那些患有基线代谢功能障碍,炎症升高和BMI较高的人.
- 这些发现表明,西作为与PCC相关的认知障碍的潜在治疗选择.
- 需要进行进一步的研究,以充分了解伏尔提奥塞丁在PCC中的有效性背后的机制.
相关概念视频
01:30Negative and Cognitive Symptoms of Schizophrenia
48
Negative symptoms of schizophrenia indicate a reduction or absence of typical behaviors and emotional responses found in healthy individuals, while positive symptoms reflect an excess or distortion of normal functioning.
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
48
01:22Alzheimer's Disease: Treatment
188
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
188
01:25Antidepressant Drugs: Overview
485
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
485
01:23Antidepressant Drugs: MAOIs and Other Agents
229
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
229